Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Clozapine: Patients of Schizophrenia receiving Clozapine will be prospectively observed for development of Metabolic Syndrome
Intervention2: NIL: NIL
Sponsors
AIIMS Raipur
Eligibility
Inclusion criteria
Inclusion criteria: 1. All genders aged between 18 years to 65 years. 2. All patients with Schizophrenia diagnosed as per International Classification of disease 10 (ICD-10). 3. Patients prescribed Clozapine. 4. Medically stable patients.
Exclusion criteria
Exclusion criteria: 1. Unstable patients i.e. patients with violence, suicide risk, and risk of harm to self/others. 2. Patients with diagnosable intellectual disability. 3. Pregnant or lactating patients. 4. Medically unstable patients. 5. Severely physical disability or locomotive disability. 6. History of substance dependence other than tea or coffee. 7. History of significant weight loss in the past month. 8. Patients on metabolism-friendly medication (Such as Aripiprazole, Brexpiprazole, Lurasidone, Topiramate etc).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of patients with Schizophrenia on Clozapine showing increased risk for metabolic syndromeTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess clozapine-related adverse drug reactions and their frequency in the study population.Timepoint: 6 months;To assess the improvement in symptomsTimepoint: 6 months;To assess the risk for developing diabetesTimepoint: 6 months;To check for adherence to Clozapine therapy in patients with schizophreniaTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactPugazhenthan Thangaraju
All India Institute of Medical Sciences (AIIMS) Raipur
Outcome results
None listed